LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
TNXP
Tonix Pharmaceuticals Holding Corp.
There isn't enough reported data to score TNXP yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
TNXP Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
TNXP's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
TNXP PE Valuation
TNXP has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
TNXP Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect TNXP's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
TNXP Earnings Per Share
TNXP and LLY do not have enough comparable growth data to identify a winner.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over TNXP on profitability, with a higher operating margin.
TNXP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $17.2M | +424% |
| Q2 2026 | $13.5M | +578% |
| Q1 2026 | $6.9M | +183% |
| Q4 2025 | $5.4M | +109% |
| Q3 2025 | $3.3M | +17% |
| Q2 2025 | $2M | -9.5% |
| Q1 2025 | $2.4M | -2.1% |
| Q4 2024 | $2.6M | -32% |
TNXP's revenue has grown year over year for five quarters in a row: $17M last quarter, up 424% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -322% | +683 points |
| Q2 2026 | -314% | +1102 points |
| Q1 2026 | -604% | +57 points |
| Q4 2025 | -896% | -25 points |
| Q3 2025 | -1005% | -454 points |
| Q2 2025 | -1416% | +2085 points |
| Q1 2025 | -661% | +199 points |
| Q4 2024 | -871% | -148 points |
TNXP's operating margin was −322% last quarter, up 683 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over TNXP on cash generation, producing positive trailing cash flow while its opponent burns cash.
TNXP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$41.7M | -$11.9M |
| Q2 2026 | -$42.8M | -$27.5M |
| Q1 2026 | -$44M | -$27.4M |
| Q4 2025 | -$41.5M | -$26.9M |
| Q3 2025 | -$29.7M | -$10.9M |
| Q2 2025 | -$15.4M | -$5.4M |
| Q1 2025 | -$16.6M | +$1.1M |
| Q4 2024 | -$14.6M | +$8.1M |
TNXP has burned cash in almost every quarter: −$170M over the past year, against −$76M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over TNXP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
TNXP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +11% | +1.8M shares |
| 1 year | +152% | +11.1M shares |
TNXP has 18M diluted shares, up 152% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $7.8M |
| Q3 2025 | — |
| Q2 2025 | $2.9M |
| Q1 2025 | $3M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $14M |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
TNXP Net Leverage
TNXP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
TNXP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.4 | Oversold |
| Stochastic | 1.2 | Oversold |
TNXP's weekly RSI is 24 (oversold) and its Stochastic is 1 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
TNXP PE vs Healthcare Sector
TNXP has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over TNXP on trend strength, trading above more of its moving averages.
TNXP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.29 | 48% below |
| 20 week MA | $9.72 | 67% below |
| 50 week MA | $12.7 | 74% below |
| 100 week MA | $20.0 | 84% below |
| 200 week MA | $1,860.9 | 100% below |
TNXP is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over TNXP on returns for 2026, with the stronger performance.
TNXP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $704,000.0 | $425,600.0 | -40% |
| 2021 | $425,600.0 | $256,064.0 | -40% |
| 2022 | $256,064.0 | $6,640.0 | -97% |
| 2023 | $6,640.0 | $1,289.6 | -81% |
| 2024 | $1,289.6 | $33.8 | -97% |
| 2025 | $33.8 | $16.3 | -52% |
| 2026 YTD | $16.3 | $3.24 | -80% |
TNXP has finished every year since 2020 lower, and it's down 80% so far in 2026.